title: Disposition of 14C-eptifibatide after intravenous administration to healthy men.
abstract: Eptifibatide, a synthetic peptide inhibitor of the platelet glycoprotein IIb/IIIa receptor, has been studied as an antithrombotic agent in a variety of acute ischemic coronary syndromes. The purpose of the present study was to characterize the disposition of 14C-eptifibatide in man after a single intravenous (i.v.) bolus dose. 14C-Eptifibatide (approximately 50 microCi) was administered to eight healthy men as a single 135-microgram/kg i.v. bolus. Blood, breath carbon dioxide, urine, and fecal samples were collected for up to 72 hours postdose and analyzed for radioactivity by liquid scintillation spectrometry. Plasma and urine samples were also assayed by liquid chromatography with mass spectrometry for eptifibatide and deamidated eptifibatide (DE). Mean (+/- SD) peak plasma eptifibatide concentrations of 879 +/- 251 ng/mL were achieved at the first sampling time (5 minutes), and concentrations then generally declined biexponentially, with a mean distribution half-life of 5 +/- 2.5 minutes and a mean terminal elimination half-life of 1.13 +/- 0.17 hours. Plasma eptifibatide concentrations and radioactivity declined in parallel, with most of the radioactivity (82.4%) attributed to eptifibatide. A total of approximately 73% of administered radioactivity was recovered in the 72-hour period following 14C-eptifibatide dosing. The primary route of elimination was urinary (98% of the total recovered radioactivity), whereas fecal (1.5%) and breath (0.8%) excretion was small. Eptifibatide is cleared by both renal and nonrenal mechanisms, with renal clearance accounting for approximately 40% of total body clearance. Within the first 24 hours, the drug is primarily excreted in the urine as unmodified eptifibatide (34%), DE (19%), and more polar metabolites (13%).
authors.affiliation: Schering-Plough Research Institute, Kenilworth, New Jersey, USA.
authors.forename: K B
authors.initials: KB
authors.lastname: Alton
authors.forename: T
authors.initials: T
authors.lastname: Kosoglou
authors.forename: S
authors.initials: S
authors.lastname: Baker
authors.forename: M B
authors.initials: MB
authors.lastname: Affrime
authors.forename: M N
authors.initials: MN
authors.lastname: Cayen
authors.forename: J E
authors.initials: JE
authors.lastname: Patrick
mesh_terms: D000328:Adult; D019540:Area Under Curve; D001711:Biotransformation; D001800:Blood Specimen Collection; D002250:Carbon Radioisotopes; D003641:Deamination; D000077542:Eptifibatide; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D010455:Peptides / Q000008:administration & dosage / Q000493:pharmacokinetics*; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000493:pharmacokinetics*
chemical_list: D002250:Carbon Radioisotopes; D010455:Peptides; D010975:Platelet Aggregation Inhibitors; D000077542:Eptifibatide